Zenosense, Inc.
ZENO
Other OTC0.00
USD
+0.00
- -
CIK
0001458581
ISIN
US9894242059
CUSIP
989424205
Return %
Stock
S&P500
1Y
50.00
26.53
3Y
-95.14
76.60
5Y
-99.71
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Zhongjian Hu
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1185 Avenue of the Americas New York City NY United States of America 10036
- IPO Date
- Apr 2, 2014
- CIK
- 0001458581
- Website
- zenosense.com
- Similar Companies
- Business
- Zenosense, Inc. operates as a healthcare technology company primarily focused on the development and commercialization of medical diagnostic devices. Its core products include the MIDS Cardiac™ system, designed for the diagnosis of acute myocardial infarction and other cardiac-related illnesses. The company also develops detection technologies targeting Methicillin-resistant Staphylococcus aureus (MRSA). Zenosense offers advanced diagnostic devices that incorporate nano-magnetic technology aimed at enhancing the accuracy and speed of cardiac and infection diagnostics. The company targets healthcare providers and diagnostic markets across the United States, with a history of operations centered in New Haven, Connecticut. Founded in 2008, Zenosense has undergone strategic name changes and business realignments, previously operating under the name Braeden Valley Mines, Inc. In recent years, Zenosense has shifted its focus toward exploring business opportunities through potential acquisitions, asset purchases, or reverse mergers, reflecting a strategic repositioning in its operational approach. The company continues to advance its diagnostic technologies in the cardiac and infectious disease segments, notably progressing with the development of the MIDS Cardiac™ platform. There have been no prominent recent partnerships or funding rounds publicly disclosed, indicating a period of internal development and preparatory restructuring focused on bringing their medical devices to market readiness. Zenosense remains headquartered in New Haven, Connecticut, and maintains its classification within the healthcare technology and medical device industries. The company has also indicated intentions to expand its business model to include acquisition opportunities in complementary healthcare technology fields. Overall, Zenosense, Inc. positions itself as a specialized medical device developer with a primary emphasis on diagnostic tools for cardiac events and bacterial infections, leveraging innovation in nano-magnetic and molecular detection technologies, while actively exploring strategic growth avenues since 2023-2024.